Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Phathom Pharmaceuticals (Nasdaq: PHAT) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team will engage in a fireside chat on Tuesday, April 8th, 2025, at 10:15 am ET.

The conference, scheduled to run from April 7-10, 2025, will also feature one-on-one meetings with company management. A live webcast and archived recording of the event will be accessible through the Events & Presentations section of Phathom's website, with the recording remaining available for 90 days after the meeting.

Phathom Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of novel treatments for gastrointestinal (GI) diseases.

FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8th, 2025, at 10:15 am ET.

Company management will also participate in one-on-one meetings during the conference, which will run from April 7-10, 2025.

To access the live webcast and archived recording of the event, visit the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recording will be available for 90 days following the conclusion of the meeting.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA^® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA^® TRIPLE PAK^® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA^® DUAL PAK^® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

FAQ

When is Phathom Pharmaceuticals (PHAT) presenting at the Needham Healthcare Conference 2025?

Phathom Pharmaceuticals will present on Tuesday, April 8th, 2025, at 10:15 am ET during a fireside chat.

How long will the recording of PHAT's Needham Conference presentation be available?

The recording will be available for 90 days following the conclusion of the conference.

Where can investors access PHAT's Needham Conference presentation webcast?

The webcast can be accessed through the Events & Presentations section of Phathom's website at investors.phathompharma.com.

What is the duration of the 2025 Needham Healthcare Conference where PHAT is presenting?

The conference runs from April 7-10, 2025.

What type of diseases does Phathom Pharmaceuticals (PHAT) focus on treating?

Phathom Pharmaceuticals focuses on developing and commercializing novel treatments for gastrointestinal (GI) diseases.